VISION
Inspiring transformational change in the
field of oncology diagnostics
MISSION
To develop and deliver accurate, rapid, minimally
invasive oncology diagnostic products utilising our
patented MCM5 antibodies
Arquer Diagnostics is focused on the development and commercialisation of highly accurate minichromosome maintenance (MCM) protein based non-invasive tests for cancer diagnosis and monitoring.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.
Latest News
Arquer Diagnostics @Arquer Diagnostics
Our latest #clinicalprogramme is centred on the detection of #endometrialcancer. With this illness more common in #women over 60 and 380,000 people affected by this in 2018, the need for this sort of #diagnostic test is greater than ever. https://t.co/x6vtWIngI1
Arquer Diagnostics @Arquer Diagnostics
#ADXBLADDER continues to provide #medicalprofessionals with an #accurate and easy-to-use test that helps them confidently exclude the presence of #bladder #cancer in their #patients. Find out how to access our essential #diagnostic technology by visiting our website. https://t.co/8cMIckwYS0
Arquer Diagnostics @Arquer Diagnostics
Earlier this month, we announced that we would be moving our #diagnostic innovation into the world of #prostatecancer detection. We have set up a #clinicalstudy for prostate cancer in ten UK #hospitals and will be looking to open a European study very soon. https://t.co/7Zn0Z96LFW
Arquer Diagnostics @Arquer Diagnostics
For many suspected of having #cancer, waiting for #results can be a challenging experience. Using #ADXBLADDER will help speed up this delicate process as our #ELISA can be run in as quickly as 2.5 hours. Find out more about ADXBLADDER by visiting our website. https://t.co/4sVRxn29i8
Arquer Diagnostics @Arquer Diagnostics
In the world of #diagnostics, #accuracy is key. #ADXBLADDER's unparalleled 99% Negative Predictive Value allows #urologists to identify cancer-negative patients with more #reliability, accuracy and #confidence than ever before. https://t.co/TGcm3u42JP
